NCT05173012: A reported trial by Sage Therapeutics
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05173012 |
|---|---|
| Title | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 5, 2022 |
| Completion date | May 2, 2024 |
| Required reporting date | May 2, 2025, midnight |
| Actual reporting date | May 1, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |